<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347331</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16-0770</org_study_id>
    <nct_id>NCT03347331</nct_id>
  </id_info>
  <brief_title>[18F]-F13640 as a New Brain Radiopharmaceutical</brief_title>
  <acronym>F13640</acronym>
  <official_title>First-in-man Study of [18F]-F13640, a PET Radiopharmaceutical for Functional 5-HT1A Receptor Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical assay is designed to validate that [18F]F13640 as a radiotracer of 5-HT1A
      functional receptors. A first group of healthy subjects underwent a PET scan with arterial
      blood sampling to determine the kinetic model of the tracer. A second group of healthy
      subjects underwent a classical test-retest study (i.e two distant PET scans) to determine the
      reproducibility of measures.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binding potentials</measure>
    <time_frame>180 minutes</time_frame>
    <description>Binding potentials are calculated using compartimental modelling techniques.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Neurological Pathology</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Input function group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject underwent a 90 min acquisition PET scan with concomitant arterial blood sampling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test-retest group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject underwent 2 PET scans distant from 1 to 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]F13640</intervention_name>
    <description>Radiotracer injection and PET scan acquisition of 90 min:
*150 Mbq + 1 MBq/Kg of [18F]F13640 at t=0 min
Arterial Blood Sampling during the 90min acquisition</description>
    <arm_group_label>Input function group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]F13640</intervention_name>
    <description>2 Radiotracer injections and PET scan acquisition of 90 min distant from 1 to 3 weeks: For each exam: 150 MBq + 1 MBq/kg of [18F]F13640 at t=0 min</description>
    <arm_group_label>Test-retest group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Subjects

          -  Weight between 50 kg and 90 kg

          -  Affiliated to a social security or similar scheme

          -  Not subject to any legal protection measures

        Exclusion Criteria:

        Subjects with neurologic or psychiatric disease including all substance addictions

          -  Daily smokers

          -  Active infectious disease

          -  MRI contraindications

          -  PET contraindications determined with FDG injection

          -  Subjects deprived of their liberty by judicial or administrative decision

          -  Subjects unable to sign written consent for participation in the study.

          -  Severe and progressive medical pathology

          -  Volunteer who has exceeded the annual amount of compensation authorized for
             participation in research protocols
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scheiber Christian</last_name>
    <role>Study Chair</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scheiber Christian</last_name>
    <phone>04 72 68 49 61</phone>
    <email>christian.scheiber@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zimmer Luc</last_name>
    <phone>04 72 68 86 20</phone>
    <email>luc.zimmer@univ-lyon1.fr</email>
  </overall_contact_backup>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET imaging- Serotonin-Radiotracer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiopharmaceuticals</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

